Trial Profile
Study of autologous stem cell transplantation (ASCT) as part of the primary therapy and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2018
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 18 May 2018 New trial record
- 01 Apr 2018 Results published in the Hematological Oncology